About vaccines

// 15.7.2022

Researchers assessed neutralizing antibody responses to SARS-CoV-2 after receiving one dose of vaccine. // 8.7.2022

Immunity against new Omicron variants is getting weaker and weaker. Is another vaccination with the available vaccines worth it? // 30.6.2022

// 23.6.2022

This cohort study uses data from the national health care databases of the US Department of Veterans Affairs to compare the risks of adverse events associated with BNT162b2 and mRNA-1273 vaccines reported among US veterans. // 13.6.2022

In a recent study posted to the medRxiv* pre-print server, researchers examined a clinical cohort of severely obese people vaccinated with coronavirus disease 2019 (COVID-19) vaccines to determine the relationship between an individual's body mass index (BMI) and COVID-19-related hospitalization and mortality. // 16.6.2022

In a recent article posted to the medRxiv* preprint server, scientists assessed the efficacy of the primary and boosted regimens of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in preventing SARS-CoV-2 Omicron-linked hospitalizations in the United States (US). // 16.6.2022

In a recent study posted to the medRxiv* pre-print server, researchers in the United Kingdom investigated the effect of two Pfizer/BioNTech BNT162b2 vaccine doses or Oxford/AstraZeneca AZ1222 coronavirus disease 2019 (COVID-19) vaccination and a subsequent BNT162b2 booster dose in a cohort of healthcare workers (HCWs) over six to nine months. // 10.6.2022

Introduction Individuals with a prior severe acute respiratory corona virus 2 (SARS-CoV-2) infection have a moderate to high degree of protection against reinfection, though seemingly less so when the Omicron variant of SARS-CoV-2 started to circulate. The aim of this study was to evaluate the vaccine effectiveness (VE) against SARS-CoV-2 reinfection, that is, in individuals with prior SARS-CoV-2 infection, during periods with different dominant SARS-CoV-2 variants. // 1.6.2022

Scientists at La Jolla Institute for Immunology have published the first analysis of how four types of COVID-19 vaccines prepare the body to fight SARS-CoV-2. // 31.5.2022

Deaths more than 80% lower in communities with high vaccination coverage A large US study published by The BMJ today finds that fewer people die from covid-19 in better vaccinated communities. The findings, based on data across 2,558 counties in 48 US states, show that counties with high vaccine coverage had a more than 80% […] // 18.5.2022

Objective To evaluate the impact of vaccine scale-up on population level covid-19 mortality and incidence in the United States. Design Observational study. Setting US county level case surveillance and vaccine administration data reported from 14 December 2020 to 18 December 2021. Participants Residents of 2558 counties from 48 US states. Main outcome measures The primary outcome was county covid-19 mortality rates (deaths/100 000 population/county week). The secondary outcome was incidence of covid-19 (cases/100 000 population/county week). Incidence rate ratios were used to compare rates across vaccination coverage levels. The impact of a 10% improvement in county vaccination coverage (defined as at least one dose of a covid-19 vaccine among adults ≥18 years of age) was estimated During the eras of alpha and delta variant predominance, the impact of very low (0-9%), low (10-39%), medium (40-69%), and high (≥70%) vaccination coverage levels was compared. Results In total, 30 643 878 cases of covid-19 and 439 682 deaths associated with covid-19 occurred over 132 791 county weeks. A 10% improvement in vaccination coverage was associated with an 8% (95% confidence interval 8% to 9%) reduction in mortality rates and a 7% (6% to 8%) reduction in incidence. Higher vaccination coverage levels were associated with reduced mortality and incidence rates during the eras of alpha and delta variant predominance. Conclusions Higher vaccination coverage was associated with lower rates of population level covid-19 mortality and incidence in the US. Centers for Disease Control and Prevention covid-19 vaccination, case, and death data are available at [data.cdc.gov][1]. [1]: http://data.cdc.gov // 11.5.2022

Haittavaikutusilmoitusjärjestelmän avulla pyritään havaitsemaan lääkkeiden ja rokotteiden harvinaisia, aiemmin tunnistamattomia haittoja // 9.5.2022

// 6.5.2022

Following a rise in cases due to the delta variant and evidence of waning immunity after 2 doses of the BNT162b2 vaccine, Israel began administering a third BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the omicron variant compared to the delta variant and that this protection wanes quickly. // 5.5.2022

Background-Two doses of the BNT162b2 vaccine yielded high effectiveness that wanes within several months. The third dose was effective in mounting a significant humoral and cellular immune response. // 5.5.2022

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic. The virus has infected more than 505 million people and caused more than 6 million deaths. However, data on non-responders to SARS-CoV-2 vaccines in the general population are limited. // 6.5.2022

A recent study published in the journal Public Library of Science (PLOS) ONE presented the T cell and humoral immune responses following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection against the SARS-CoV-2 original and mutant strains. // 27.4.2022

In a recent study published in the Nature Medicine journal, the researchers assessed the effectiveness of a second booster dose of the BioNTech, Pfizer BNT162b2 vaccine against coronavirus disease 2019 (COVID-19) severity in elderly patients. // 26.4.2022

Nature Medicine - A retrospective analysis of data from a large healthcare insurance provider in Israel demonstrates that administration of a second booster shot (fourth dose) of BNT162b2 in people... // 25.4.2022

// 24.4.2022

Researchers assessed the impact of SARS-CoV-2 mRNA booster vaccine on the SARS-CoV-2 Omicron variant. // 22.4.2022

Researchers investigate the duration of effectiveness of mRNA-based COVID-19 vaccines in preventing ICU admission. // 21.4.2022

This report describes COVID-19 mRNA vaccination effectiveness in preventing COVID-19 hospitalizations among people previously infected. // 15.4.2022

A recent study assessed the prevalence of SARS-CoV-2 symptoms and the risk of hospitalization in vaccinated individuals infected with SARS-CoV-2 Omicron and Delta variants. // 12.4.2022

75-year literature review finds incidence no different than following non-COVID vaccines // 11.4.2022

Background: We estimated SARS-CoV-2 Delta and Omicron-specific effectiveness of 2 and 3 mRNA COVID-19 vaccine doses in adults against symptomatic illness in US outpatient settings. // 10.4.2022

The study objective was to explore state death rates pre- and post- 4/19/2021 (date vaccines were assumed available) and the relative contributions of 3 factors to state death rates post- 4/19/2021: 1) vaccination rates, 2) prevalence of obesity, hypertension, diabetes, COPD, cardiovascular disease, and asthma and 3) red vs. blue states, to better understand options for reducing deaths. The ratio of red to blue state deaths/million was 1.6 pre-4/19/2021 and 2.3 between 4/19 and 2/28/2022 resulting in 222,000 extra deaths in red states or 305/ day. // 10.4.2022

This report describes the risk for cardiac complications as higher after COVID-19 infection that after COVID-19 vaccination for males and females in all age groups. // 8.4.2022

Nature Medicine - The infectious viral load of SARS-CoV-2 Omicron is lower than that of Delta in symptomatic breakthrough infections of recipients of two doses of a COVID-19 vaccine, suggesting... // 8.4.2022